Science and Tech

Peptide Cancer Vaccine Global Market Research Report 2018


Peptide Cancer Vaccine6871.jpg

This report studies the Peptide Cancer Vaccine market status and outlook of global and major regions, from angles of manufacturers, regions, product types and end industries; this report analyzes the top manufacturers in global and major regions, and splits the Peptide Cancer Vaccine market by product type and applications/end industries.

The major players in global Peptide Cancer Vaccine market include

  • TapImmune
  • BrightPath Biotherapeutics
  • Ultimovacs
  • Sellas
  • Boston Biomedical
  • Imugene
  • VAXON Biotech
  • Generex Biotechnology
  • ISA Pharmaceuticals
  • OncoTherapy Science
  • Immatics

Download free sample PDF of this report @ https://www.grandresearchstore.com/report-sample/peptide-cancer-vaccine-market-15

Geographically, this report is segmented into several key Regions, with revenue, market share and growth rate of Peptide Cancer Vaccine in these regions, from 2012 to 2023 forecast, covering

  • USA
  • Europe
  • China
  • Japan
  • South America
  • RoW

On the basis on the end users/applications, this report covers

  • Breast Cancer
  • Lung Cancer
  • Melanoma
  • Prostate Cancer
  • Others

Browse full report @https://www.grandresearchstore.com/life-sciences/peptide-cancer-vaccine-market-15

Table of Contents

1 Peptide Cancer Vaccine Market Overview 1
1.1 Peptide Cancer Vaccine Product Overview 1
1.2 Peptide Vaccine Strategies in the Treatment of Cancer 1
1.3 Global Peptide Cancer Vaccine Segment by Applications 4
1.3.1 Global Peptide Cancer Vaccine Revenue Market Share by Applications in 2025 4
1.3.2 Breast Cancer 4
1.3.3 Lung Cancer 5
1.3.4 Melanoma 6
1.3.5 Prostate Cancer 7
1.4 Global Peptide Cancer Vaccine Market by Regions 20202030 8
1.4.1 Global Peptide Cancer Vaccine Market Size and Growth Rate Comparison by Regions 20202030 8
1.4.2 USA Peptide Cancer Vaccine Status and Prospect 20202030 9
1.4.3 Europe Peptide Cancer Vaccine Status and Prospect 20202030 10
1.4.4 Japan Peptide Cancer Vaccine Status and Prospect 20202030 11
1.5 Global Peptide Cancer Vaccine Market Size 20202030 12
1.6 Global Manufacturers Peptide Cancer Vaccine Headquarters, Established and Product 12


2 Cancer Vaccines and Immunotherapy 14
2.1 Therapeutic Vaccines 14
2.1.1 Autologous Cancer Vaccines 15
2.1.2 Allogenic Cancer Vaccines 16
2.1.3 Protein or Peptide Cancer Vaccines 16
2.1.4 DNA Vaccines 16
2.2 Other Approaches 16
2.3 Clinical Considerations for Therapeutic Cancer Vaccines 17
2.3.1 Considerations for both Early and Late Phase Clinical Trials 18
2.3.2 Considerations for Early Phase Clinical Trials 18
2.3.3 Considerations for Late Phase Clinical Trials 19


3 Wide Spectrum Action of Peptide Cancer Vaccines against Major Cancer 20
3.1 Peptides & Colorectal Cancer 20
3.1.1 Colorectal Cancer Introduction 20
3.1.2 Introduction of the Number of Patients with Colorectal Cancer 20
3.1.3 Peptide Cancer Vaccine Introduction about Colorectal Cancer 21
3.2 Peptides & Lung Cancer 22
3.2.1 Lung Cancer Introduction 22
3.2.2 Introduction of the Number of Patients with Lung Cancer 23
3.2.3 Peptide Cancer Vaccine Introduction about Lung Cancer 25
3.3 Peptides & Pancreatic Cancer 26
3.3.1 Pancreatic Cancer Introduction 26
3.3.2 Introduction of the Number of Patients with Pancreatic Cancer 27
3.3.3 Peptide Cancer Vaccine Introduction about Pancreatic Cancer 28
3.4 Peptides & Breast Cancer 29
3.4.1 Breast Cancer Introduction 29
3.4.2 Introduction of the Number of Patients with Breast Cancer 29
3.4.3 Peptide Cancer Vaccine Introduction about Breast Cancer 30
3.5 Peptides & Prostate Cancer 31
3.5.1 Prostate Cancer Introduction 31
3.5.2 Introduction of the Number of Patients with Prostate Cancer 32
3.5.3 Peptide Cancer Vaccine Introduction about Prostate Cancer 33
3.6 Peptides & Other Cancer 34


4 Global Peptide Cancer Vaccine by Pipeline 37
4.1 ITK1 37
4.2 GRN1201 38
4.3 TPIV200 40
4.4 TPIV110 40
4.5 UV1 41
4.6 galinpepimutS 42
4.7 TARP 2735 42
4.8 HERVaxx 43
4.9 Vx001 45
4.10 Vx006 46
4.11 Vx016 46
4.12 AE37 47
4.13 ISA101 HPV 49
4.14 MyISA Personalized immunotherapy based on neoantigens 50
4.15 ISA203 PRAME 51
4.16 ISA204 HBV 51
4.17 OTSA101 52
4.18 GALINPEPIMUTS AND KEYTRUDA PEMBROLIZUMAB 53
4.19 ACTolog 54
4.20 DSP7888 Dosing Emulsion plus Bevacizumab 55
4.21 DSP7888 in Patients with Myelodysplastic Syndrome MDS 55
4.22 DSP7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas 56
4.23 DSP7888 Dosing Emulsion in Adult Patients With Advanced Malignancies 56


5 Global Cancer Vaccine Consumption by Regions 20122017 57
5.1 Global Cancer Vaccine Consumption by Regions 20122017 57
5.2 North America Cancer Vaccine Consumption 20122017 61
5.3 Europe Cancer Vaccine Consumption 20122017 63
5.4 China Cancer Vaccine Consumption 20122017 65

If You Have Any Question Related To This Report Contact Us @ https://www.grandresearchstore.com/enquire-now/peptide-cancer-vaccine-market-15

Contact Us:

276 5th Avenue, New York , NY 10001, United States

Int’l: +1(212)-634–4884 / +1(646)-781–7170

Fax: +1(212)-634–4885

[email protected]

Follow Us On linkedin :- https://www.linkedin.com/company/grand-research-store





Grand Research Store

simran kaur

GR-Store has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.